个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共10条记录   Anti-Proliferative Compounds for the Prevention of Restenosis: Anti-Restenotic Mechanisms of Paclitaxel Action [作者：Lavigne, MC; Eppihimer, MJ; Cheng, R; Barry, JJ,期刊：Current Pharmaceutical Design, 页码：3989-4001 , 文章类型： Review，,卷期：2010年16-36] Coronary artery disease is commonly characterized by atherosclerotic obstruction of vessels responsible for providing adequate blood supply to the myocardium. Disruption of atheromatous plaques can promote thrombosis, si... Biodegradable and Bioabsorbable Stents [作者：Waksman, R; Pakala, R,期刊：Current Pharmaceutical Design, 页码：4041-4051 , 文章类型： Review，,卷期：2010年16-36] Angioplasty of the coronary arteries has made significant headway in the past 20 years as a treatment for atherosclerotic vascular disease. Though drug-eluting stents are effective, they appear to invoke a thrombogenic r... Clinical Studies with Paclitaxel - Eluting Stent Systems [作者：Bajaj, NR; Garratt, KN,期刊：Current Pharmaceutical Design, 页码：4025-4036 , 文章类型： Review，,卷期：2010年16-36] Coronary artery stents mechanically buttress the arterial wall and prevent negative remodeling, leading to increased lumen gain and less angiographic and clinical restenosis when compared to balloon angioplasty alone. Al... Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug-Eluting Stent Systems [作者：Claessen, BE; Henriques, JPS; Dangas, GD,期刊：Current Pharmaceutical Design, 页码：4012-4024 , 文章类型： Review，,卷期：2010年16-36] The introduction of the drug-eluting stent (DES) has revolutionized the field of interventional cardiology during the past decade. Initial pivotal randomized clinical trials showed a large reduction in restenosis rates a... Current Status of Drug Eluting Stents [作者：Kipshidze, N,期刊：Current Pharmaceutical Design, 页码：3977-3977 , 文章类型： Editorial Material，,卷期：2010年16-36] Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation [作者：Vorpahl, M; Yazdani, SK; Nakano, M; Ladich, E; Kolodgie, FD; Finn, AV; Virmani, R,期刊：Current Pharmaceutical Design, 页码：4064-4071 , 文章类型： Review，,卷期：2010年16-36] First generation drug-eluting stents (DES) have significantly improved the treatment options for patients with symptomatic coronary artery disease by decreasing rates of acute vessel closure and restenosis after percutan... Drug Eluting Stents for Vulnerable Plague [作者：Toutouzas, K; Synetos, A; Stefanadis, C,期刊：Current Pharmaceutical Design, 页码：4037-4040 , 文章类型： Review，,卷期：2010年16-36] A vulnerable plaque is an atheromatic plaque with specific morphological characteristics, mainly presented as an unstable collection of white blood cells and lipids in the wall of an artery. It is of great importance to ... Polymers for Drug Eluting Stents [作者：Parker, T; Dave, V; Falotico, R,期刊：Current Pharmaceutical Design, 页码：3978-3988 , 文章类型： Review，,卷期：2010年16-36] Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to th... Sirolimus and its Analogs and its Effects on Vascular Diseases [作者：Adelman, SJ,期刊：Current Pharmaceutical Design, 页码：4002-4011 , 文章类型： Review，,卷期：2010年16-36] Sirolimus (rapamycin), a macrolide antibiotic approved for use as an immunosuppressive agent in the prevention of organ rejection, is a cell proliferation inhibitor and regulator of the immune response which acts through... Stent Thrombosis and Duration of Dual Antiplatelet Therapy [作者：Ielasi, A; Al-Lamee, R; Colombo, A,期刊：Current Pharmaceutical Design, 页码：4052-4063 , 文章类型： Review，,卷期：2010年16-36] Stent thrombosis (ST) is a rare complication following coronary stenting; however given the associated serious consequences, in particular death and myocardial infarction, it remains a source of considerable concern for ...